Anavex Life Sciences Corp (AVXL)

[nidan7500]

On July 5, Biogen issued a press release stating BAN2401 showed a statistically significant reduction in slowing the Alzheimer's Disease Composite Score, a key indicator of disease activity. The announcement came as a great surprise as the product was virtually written off six months ago when it failed its initial clinical trial. Biogen did not reveal the entirety of the data set underscoring just how difficult it will be to handicap the commercial viability of the product. The share price of Biogen jumped ~15% upon the recent data release, underscoring the critical importance a new line of therapy is for Biogen.

Seeking alpha link today. The bolded part is a gap that seems contradictory with the claim. This is an indication of just what precision medicine is not. They should have been laughed off the stage.